-
2022-501308-90-00
4
2023-05-24
Molecularly selected and resectable primary colorectal cancer
-
2024-512878-98-00
9
2023-05-16
Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative
Breas
-
2022-501894-37-00
4
2023-03-02
prostate cancer
-
2024-511631-10-00
9
2023-02-27
Hodgkin’s lymphoma
-
2024-515354-24-00
9
2022-05-18
Low risk myelodysplastic syndrom without RS having failed or being ine
-
2023-503651-10-00
7
2022-05-17
Male and female participants ≥ 18 years of age with advanced or
metast
-
2024-515681-14-00
4
2022-05-02
Stage II (pT4)/III colorectal cancer with positive circulating tumor D
-
2022-502425-18-00
5
2022-04-19
Adenocarcinoma of the prostate
-
2024-513820-40-00
4
2021-10-29
Metastatic or locally advanced leiomyosarcoma
-
2024-514319-85-00
4
2021-09-14
Advanced rearranged mesenchymal chondrosarcoma
-
2024-511246-39-00
1
2021-07-27
Solid tumours with HER2 aberrations
-
2024-512953-26-00
5
2021-07-06
intermediate-stage hepatocellular carcinoma
-
2024-512982-15-00
5
2021-06-28
BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metas
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2023-508094-88-00
5
2021-02-08
breast cancer
-
2024-513372-18-00
4
2019-10-18
Pre- and post-menopausal women with HR+/HER2- LABC or MBC whose diseas
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2023-506987-15-00
9
2016-11-17
Metastatic Castration-Resistant Prostate Cancer
-
2024-519773-19-00
5
2025-07-31
Gastroesophageal Junction Adenocarcinoma
-
2024-512504-19-00
1
2025-05-28
solid tumors
-
2024-513621-23-00
5
2025-04-18
Advanced/metastatic non-small cell lung cancer (NSCLC)
-
2024-512180-31-00
4
2025-03-14
Oligometastatic renal cell carcinoma
-
2024-512998-27-00
5
2025-02-21
Non-Small Cell Lung Cancer
-
2023-506049-52-00
4
2024-10-28
Follicular lymphoma